Immunitybio Inc (IBRX)

$7.72 -0.20 (-2.53%)
Market Cap 8.39B
Revenue (ttm) 113.29M
Net Income (ttm) -351.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.18%
Debt to Equity Ratio 0.00
Volume 5,412,800
Avg Vol 10,609,420
Day's Range N/A - N/A
Shares Out 1.06B
Stochastic %K 69%
Beta 0.03
Analysts Strong Sell
Price Target $11.62

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
Jhankster60
Jhankster60 Aug. 19 at 12:17 PM
$IBRX ‘Bearish sentiment’ at 36. What a joke. Trolls working hard to paint a dire picture. Desperate. Nervous, perhaps? An ‘epiphany’ moment is coming soon for IBRX, the Company, and its investors. Nasdaq gets battered, startup biotechs get hammered while big pharmas tick up; and regarding IBRX, pps goes down on little volume giving smart investors the opportunity to load up. A pattern going on for months. The reason our tradable float is shrinking, and shrinking fast. Something’s gotta give with this 134M short volume. The springs are coiled waiting to explode. You think PSS doesn’t watch this situation daily? Think again. He does. For Longs, our time will come. GL$$$😎
0 · Reply
pietro23
pietro23 Aug. 19 at 12:16 PM
$IBRX dont forget, we are approved for non small lung cancer in SA. ....
0 · Reply
juanfermaint
juanfermaint Aug. 19 at 12:16 PM
$IBRX Mark needs to buy us a one for one. I’d be happy.
0 · Reply
crabbypatty31
crabbypatty31 Aug. 19 at 12:16 PM
$IBRX Very nice! Kissing that $8 level in the pm:)
0 · Reply
Slipvayne99
Slipvayne99 Aug. 19 at 12:14 PM
$IBRX
0 · Reply
Runmaster83
Runmaster83 Aug. 19 at 12:14 PM
$IBRX Getting that Cancer Vaccine sympathy bump…..Hint: Ours will be better! 💉
0 · Reply
STLMO
STLMO Aug. 19 at 12:14 PM
$IBRX Hello $8. This is long overdue. With this low volume it’s hard for hedgies to cover but a few shares. It’s obvious they have no exit with 129 million short. The cell door is locked for the hedgies. Disgusting betting against a cancer cure. Karma says hello.
0 · Reply
Runmaster83
Runmaster83 Aug. 19 at 12:12 PM
$IBRX https://immunitybio.com/immunitybio-announces-full-accrual-of-first-two-phases-of-cancer-vaccine-trial-in-participants-with-lynch-syndrome-and-initiation-of-randomized-controlled-phase-of-the-trial/
0 · Reply
Rach7117
Rach7117 Aug. 19 at 12:11 PM
$IBRX let’s gooo Back above 8 today
0 · Reply
Regard1plus1is5
Regard1plus1is5 Aug. 19 at 12:11 PM
$IBRX Move that resistance level bus!!!
0 · Reply
Latest News on IBRX
ImmunityBio appoints Kim as Vice Chairman

2026-08-10T13:10:26.000Z - 8 days ago

ImmunityBio appoints Kim as Vice Chairman

IBRX

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

Aug 10, 2026, 9:00 AM EDT - 8 days ago

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

IBRX

ImmunityBio reports Q2 EPS (22c) vs. (10c) last year

2026-08-04T11:45:42.000Z - 15 days ago

ImmunityBio reports Q2 EPS (22c) vs. (10c) last year

IBRX

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

Aug 4, 2026, 7:30 AM EDT - 15 days ago

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

IBRX

ImmunityBio Earnings release: Q2 2026

Aug 4, 2026, 7:30 AM EDT - 15 days ago

ImmunityBio Earnings release: Q2 2026

ImmunityBio Quarterly report: Q2 2026

Aug 4, 2026, 7:30 AM EDT - 15 days ago

ImmunityBio Quarterly report: Q2 2026

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

Jul 29, 2026, 6:45 PM EDT - 20 days ago

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

IBRX

ImmunityBio Transcript: AGM 2026

Jun 9, 2026, 1:30 PM EDT - 2 months ago

ImmunityBio Transcript: AGM 2026

ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 2 months ago

ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Jun 1, 2026, 1:51 PM EDT - 2 months ago

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

IBRX

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

May 25, 2026, 11:05 AM EDT - 3 months ago

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

IBRX

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

May 22, 2026, 3:08 PM EDT - 3 months ago

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

IBRX

DEADLINE NEXT WEEK: Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors to Contact the Firm Before May 26, 2026

May 22, 2026, 8:41 AM EDT - 3 months ago

DEADLINE NEXT WEEK: Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors to Contact the Firm Before May 26, 2026

IBRX

ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026

2026-05-22T11:52:03.000Z - 3 months ago

ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026

IBRX

ImmunityBio presents health economic analysis on ANKTIVA plus BCG

2026-05-22T11:49:46.000Z - 3 months ago

ImmunityBio presents health economic analysis on ANKTIVA plus BCG

IBRX

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

IBRX

ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA

2026-05-20T01:35:07.000Z - 3 months ago

ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA

IBRX

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

May 19, 2026, 8:30 PM EDT - 3 months ago

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

IBRX

ImmunityBio announces results from ITC analyses of NAI with BCG

2026-05-19T11:42:41.000Z - 3 months ago

ImmunityBio announces results from ITC analyses of NAI with BCG

IBRX

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

IBRX

ImmunityBio announces five U.S. patents issued for Anktiva with BCG

2026-05-18T11:48:56.000Z - 3 months ago

ImmunityBio announces five U.S. patents issued for Anktiva with BCG

IBRX

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

May 18, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

IBRX

ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory

2026-05-17T15:45:06.000Z - 3 months ago

ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory

IBRX

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

May 16, 2026, 1:35 PM EDT - 3 months ago

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

IBRX

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

May 15, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

IBRX INKT

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

May 14, 2026, 8:30 AM EDT - 3 months ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GTBP

ImmunityBio price target lowered to $12 from $13 at BTIG

2026-05-08T12:57:59.000Z - 3 months ago

ImmunityBio price target lowered to $12 from $13 at BTIG

IBRX

ImmunityBio reports Q1 EPS (62c) vs (15c) last year

2026-05-07T14:33:22.000Z - 3 months ago

ImmunityBio reports Q1 EPS (62c) vs (15c) last year

IBRX

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

May 7, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

IBRX

ImmunityBio Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Earnings release: Q1 2026

ImmunityBio Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Quarterly report: Q1 2026

ImmunityBio presents new comparison results on Anktiva, TAR-200

2026-05-05T11:51:28.000Z - 3 months ago

ImmunityBio presents new comparison results on Anktiva, TAR-200

IBRX

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

May 5, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

IBRX

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

Apr 30, 2026, 9:00 AM EDT - 3 months ago

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

IBRX

ImmunityBio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

ImmunityBio Proxy statement: Proxy filing

ImmunityBio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

ImmunityBio Proxy statement: Proxy filing

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt

Apr 23, 2026, 9:00 AM EDT - 4 months ago

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt

IBRX

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

Apr 21, 2026, 11:21 AM EDT - 4 months ago

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

IBRX

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

2026-04-21T11:56:04.000Z - 4 months ago

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

IBRX

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

Apr 21, 2026, 7:30 AM EDT - 4 months ago

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

IBRX

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 20, 2026, 4:29 PM EDT - 4 months ago

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

IBRX

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

Apr 16, 2026, 9:00 AM EDT - 4 months ago

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

IBRX

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

Apr 15, 2026, 8:00 PM EDT - 4 months ago

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

IBRX

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 15, 2026, 9:36 AM EDT - 4 months ago

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

IBRX

ImmunityBio reports preliminary Q1 net product revenue $44.2M

2026-04-09T12:01:21.000Z - 4 months ago

ImmunityBio reports preliminary Q1 net product revenue $44.2M

IBRX

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

Apr 9, 2026, 7:30 AM EDT - 4 months ago

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

IBRX

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

Apr 8, 2026, 6:00 PM EDT - 4 months ago

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

IBRX

ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance

2026-04-06T11:36:39.000Z - 4 months ago

ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance

IBRX

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Apr 6, 2026, 7:30 AM EDT - 4 months ago

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

IBRX

ImmunityBio announces $100M of financing transactions

2026-03-31T11:43:01.000Z - 5 months ago

ImmunityBio announces $100M of financing transactions

IBRX

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Mar 31, 2026, 7:30 AM EDT - 5 months ago

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

IBRX

Jhankster60
Jhankster60 Aug. 19 at 12:17 PM
$IBRX ‘Bearish sentiment’ at 36. What a joke. Trolls working hard to paint a dire picture. Desperate. Nervous, perhaps? An ‘epiphany’ moment is coming soon for IBRX, the Company, and its investors. Nasdaq gets battered, startup biotechs get hammered while big pharmas tick up; and regarding IBRX, pps goes down on little volume giving smart investors the opportunity to load up. A pattern going on for months. The reason our tradable float is shrinking, and shrinking fast. Something’s gotta give with this 134M short volume. The springs are coiled waiting to explode. You think PSS doesn’t watch this situation daily? Think again. He does. For Longs, our time will come. GL$$$😎
0 · Reply
pietro23
pietro23 Aug. 19 at 12:16 PM
$IBRX dont forget, we are approved for non small lung cancer in SA. ....
0 · Reply
juanfermaint
juanfermaint Aug. 19 at 12:16 PM
$IBRX Mark needs to buy us a one for one. I’d be happy.
0 · Reply
crabbypatty31
crabbypatty31 Aug. 19 at 12:16 PM
$IBRX Very nice! Kissing that $8 level in the pm:)
0 · Reply
Slipvayne99
Slipvayne99 Aug. 19 at 12:14 PM
$IBRX
0 · Reply
Runmaster83
Runmaster83 Aug. 19 at 12:14 PM
$IBRX Getting that Cancer Vaccine sympathy bump…..Hint: Ours will be better! 💉
0 · Reply
STLMO
STLMO Aug. 19 at 12:14 PM
$IBRX Hello $8. This is long overdue. With this low volume it’s hard for hedgies to cover but a few shares. It’s obvious they have no exit with 129 million short. The cell door is locked for the hedgies. Disgusting betting against a cancer cure. Karma says hello.
0 · Reply
Runmaster83
Runmaster83 Aug. 19 at 12:12 PM
$IBRX https://immunitybio.com/immunitybio-announces-full-accrual-of-first-two-phases-of-cancer-vaccine-trial-in-participants-with-lynch-syndrome-and-initiation-of-randomized-controlled-phase-of-the-trial/
0 · Reply
Rach7117
Rach7117 Aug. 19 at 12:11 PM
$IBRX let’s gooo Back above 8 today
0 · Reply
Regard1plus1is5
Regard1plus1is5 Aug. 19 at 12:11 PM
$IBRX Move that resistance level bus!!!
0 · Reply
Earis
Earis Aug. 19 at 12:09 PM
$IBRX hmmm interesting
1 · Reply
zoopie10
zoopie10 Aug. 19 at 12:09 PM
$IBRX if only this would move like my Moderna this morning I could finally buy that new house I’ve been wanting 🤪
1 · Reply
Runmaster83
Runmaster83 Aug. 19 at 12:08 PM
$IBRX Just imagine when our cancer vaccine gets approved. Wouldn’t touch a Moderna product with the life of my enemy.
1 · Reply
ARodgeBaby
ARodgeBaby Aug. 19 at 12:08 PM
$IBRX
0 · Reply
Trijack
Trijack Aug. 19 at 12:07 PM
$IBRX tick tock
0 · Reply
jstocks100
jstocks100 Aug. 19 at 12:07 PM
$IBRX I don't wanna get overly excited but LFG‼️ Super
0 · Reply
LB19
LB19 Aug. 19 at 12:07 PM
$MRK needs $IBRX Anktiva to be more effective. Many cancer patients are immunocompromised thanks standard care treatment wiping out lymphocytes. Anktiva regenerates lymphocytes and would creative an environment for Keytruda to be far more effective. From what I understand simply is Keytruda needs T-cells and Anktiva increases the number of T-cells. In my option $MRK should be throwing money bags at immunitybio at least to partner with them.
0 · Reply
topstockalerts
topstockalerts Aug. 19 at 12:02 PM
$IBRX buying pressure is increasing
0 · Reply
PastaSlobCFA
PastaSlobCFA Aug. 19 at 12:01 PM
$IBRX is the Moderna/Merck news bad for us?
4 · Reply
John_morrris
John_morrris Aug. 19 at 11:57 AM
$IBRX Sharing FWIW (Hoping for the best) https://x.com/houmanhemmati/status/2089892044915568856
0 · Reply
Catredeye
Catredeye Aug. 19 at 11:53 AM
$IBRX Anyone that would put MRNA poison in their body is crazy. After the Covid debacle and a brain stem stroke later. I would have preferred taking a lose of my job than the jab. This shit is dangerous. I trust Immunity Bio only at this point.
0 · Reply
jstocks100
jstocks100 Aug. 19 at 11:52 AM
$IBRX Robinhood says Short inventory: none. Think this is the first time I seen this. 🤔🤑
1 · Reply